Research programme: antibacterials - Essential Therapeutics/Schering-Plough

Drug Profile

Research programme: antibacterials - Essential Therapeutics/Schering-Plough

Latest Information Update: 29 Aug 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator
  • Developer Essential Therapeutics [CEASED]; Schering-Plough
  • Class Small molecules
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Bacterial infections

Most Recent Events

  • 22 Feb 2005 NeoGenesis has been acquired and merged into Schering-Plough
  • 04 Oct 2004 Essential Therapeutics has closed down
  • 09 Nov 2001 Microcide Pharmaceuticals has merged with Althexis to form Essential Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top